Close Menu

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity said today that it has initiated coverage of liquid biopsy firm Guardant Health with a Buy rating and a price target of $90.

In a note to investors, analyst Mark Massaro said that he views Guardant as the leader in liquid biopsy cancer testing, adding that that stock gains so far have been justified and predicted that its shares will rise further. He estimated that the Guardant360 test is less than 5 percent penetrated in a $6 billion market for liquid biopsy therapy selection in advanced cancer patients.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.